➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
McKesson
Express Scripts
Colorcon

Last Updated: May 27, 2020

DrugPatentWatch Database Preview

DECITABINE Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Decitabine, and when can generic versions of Decitabine launch?

Decitabine is a drug marketed by Accord Hlthcare, Chemi Spa, Cipla, Dr Reddys, Ingenus Pharms Llc, Lupin Ltd, MSN, Pharmascience Inc, Sagent Pharms Inc, Sandoz Inc, Wockhardt Bio Ag, and Sun Pharma Global. and is included in twelve NDAs.

The generic ingredient in DECITABINE is decitabine. There are eighteen drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the decitabine profile page.

US ANDA Litigation and Generic Entry Outlook for Decitabine

A generic version of DECITABINE was approved as decitabine by DR REDDYS on July 11th, 2013.

  Start Trial

Drug patent expirations by year for DECITABINE
Drug Prices for DECITABINE

See drug prices for DECITABINE

Recent Clinical Trials for DECITABINE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Beijing Tongren HospitalPhase 2
University of WashingtonPhase 2
Case Comprehensive Cancer CenterEarly Phase 1

See all DECITABINE clinical trials

Pharmacology for DECITABINE
Synonyms for DECITABINE
1,3, 5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy--D-erythro-pentofuranosyl)-
1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-
2-deoxyazacytidine
2-Desoxy-5-azacytidine
2'-Deoxy-5-azacytidine
22432-95-7
2353-33-5
353A335
4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-?-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-deoxy-beta-d-erythro-pentofuranosyl)-s-triazin-2(1h)-on
4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one
4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-(2-deoxy-ss-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one
5-aza-2-deoxycytidine
5-Aza-2'-deoxycytidine
5-Aza-2'-deoxycytidine, >=97%
5-Aza-2'-deoxycytidine, 98%
5-Aza-2′-Deoxycytidine
5-aza-CdR
5-aza-dC
5-Aza-deoxycytidine
5-AZAdC
5-Azadeoxycytidine
5-Deoxy-2′-azacytidine
5A2dc
776B62CQ27
AB0020011
AB00918337_08
AB00918337-07
ABP001084
AC-1135
ACT00147
AKOS015895047
Alpha-Decitibine
ANW-25144
API0002229
AS-17558
AzadC
BCP02870
BCP0726000271
BCP9000593
BDBM96274
BIFK0051
BRN 0617982
C-13049
C8H12N4O4
CA-714
CAS-2353-33-5
CC-26303
cc-571
CCG-208143
CCRIS 8227
CHEBI:50131
CHEMBL1201129
cid_451668
CS-0372
CTK1A2018
D03665
Dac
Dacogen
Dacogen (TN)
DB-029060
DB01262
decitabine (2 inverted exclamation marka-deoxy-5-azacytidine).cd
Decitabine (NSC127716, 5AZA-CdR)
Decitabine (USAN/INN)
Decitabine [USAN:INN:BAN]
deoxy-5-azacytidine
Dezocitidine
DSSTox_CID_10432
DSSTox_GSID_30432
DSSTox_RID_78849
DTXSID7030432
E-7373
EINECS 219-089-4
EOS114
EX-A961
FT-0082622
GTPL6805
HMS2235O03
HMS3413L07
HMS3677L07
HY-A0004
J-700084
J10097
JNJ 30979754
JNJ-30979754
MFCD00043011
MLS001332587
MLS001332588
MLS006010136
MolMap_000063
NCGC_5ADOC
NCGC00166088-01
NCGC00166088-02
NCGC00166088-05
NSC 127716
NSC-127716
NSC127716
PubChem19115
Q1181878
s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-
s1200
SB18982
SC-19951
SCHEMBL4006
SMR000857076
SR-01000838879
SR-01000838879-4
SW218076-2
SYN3036
Tox21_112311
Tox21_112311_1
UNII-776B62CQ27
V0702
W-5049
XAUDJQYHKZQPEU-KVQBGUIXSA-N
ZINC16929327

US Patents and Regulatory Information for DECITABINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare DECITABINE decitabine INJECTABLE;INTRAVENOUS 203475-001 Feb 27, 2017 AP RX No No   Start Trial   Start Trial   Start Trial
Msn DECITABINE decitabine INJECTABLE;INTRAVENOUS 212265-001 Aug 28, 2019 AP RX No No   Start Trial   Start Trial   Start Trial
Dr Reddys DECITABINE decitabine INJECTABLE;INTRAVENOUS 203131-001 Jul 11, 2013 AP RX No No   Start Trial   Start Trial   Start Trial
Sun Pharma Global DECITABINE decitabine POWDER;INTRAVENOUS 205582-001 Jan 28, 2014 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Dow
McKesson
Express Scripts
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.